Tricyclic Antidepressants
Tricyclic Antidepressants is a topic covered in the Washington Manual of Medical Therapeutics.
To view the entire topic, please log in or purchase a subscription.
The Washington Manual is an award-winning, complete mobile solution for nurses and students. Look up information on diseases, tests, and procedures; then consult the database with 5,000+ drugs or refer to 65,000+ dictionary terms. Explore these free sample topics:
-- The first section of this topic is shown below --
General Principles
- TCAs have fallen out of favor as first-line treatment for major depressive disorder due to their significant toxicity in overdose.
- TCAs are still prescribed for depression as second-line agents and are also utilized for migraine prophylaxis, neuropathic pain, sleep, and pruritus.
- A number of other medications are structurally homologous to the TCAs and have similar effects in overdose: diphenhydramine and other first-generation antihistamines, cyclobenzaprine (does not cause cardiac toxicity or seizure in overdose), carbamazepine (cerebellar dysfunction also present in overdose).
Pathophysiology
- TCAs antagonize a wide variety of receptors, ion channels, and pumps in overdose. Their actions on these molecular targets predict their clinical effects.
- Serotonin and norepinephrine reuptake pumps: may contribute to the development of serotonin syndrome
- Cardiac sodium channel: QRS prolongation, ventricular dysrhythmias, cardiogenic shock
- IKr potassium channel: QT interval prolongation
- Muscarinic acetylcholine receptor: antimuscarinic toxidrome
- H1 histamine receptor: somnolence
- Alpha-1 adrenoceptor: peripheral vasodilation, hypotension, tachycardia
- GABA-A receptor: seizures
-- To view the remaining sections of this topic, please log in or purchase a subscription --
General Principles
- TCAs have fallen out of favor as first-line treatment for major depressive disorder due to their significant toxicity in overdose.
- TCAs are still prescribed for depression as second-line agents and are also utilized for migraine prophylaxis, neuropathic pain, sleep, and pruritus.
- A number of other medications are structurally homologous to the TCAs and have similar effects in overdose: diphenhydramine and other first-generation antihistamines, cyclobenzaprine (does not cause cardiac toxicity or seizure in overdose), carbamazepine (cerebellar dysfunction also present in overdose).
Pathophysiology
- TCAs antagonize a wide variety of receptors, ion channels, and pumps in overdose. Their actions on these molecular targets predict their clinical effects.
- Serotonin and norepinephrine reuptake pumps: may contribute to the development of serotonin syndrome
- Cardiac sodium channel: QRS prolongation, ventricular dysrhythmias, cardiogenic shock
- IKr potassium channel: QT interval prolongation
- Muscarinic acetylcholine receptor: antimuscarinic toxidrome
- H1 histamine receptor: somnolence
- Alpha-1 adrenoceptor: peripheral vasodilation, hypotension, tachycardia
- GABA-A receptor: seizures
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Bhat, Pavat, et al., editors. "Tricyclic Antidepressants." Washington Manual of Medical Therapeutics, 35th ed., Wolters Kluwer Health, 2016. The Washington Manual, www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602655/all/Tricyclic_Antidepressants.
Tricyclic Antidepressants. In: Bhat PP, Dretler AA, Gdowski MM, et al, eds. Washington Manual of Medical Therapeutics. Wolters Kluwer Health; 2016. https://www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602655/all/Tricyclic_Antidepressants. Accessed March 24, 2023.
Tricyclic Antidepressants. (2016). In Bhat, P., Dretler, A., Gdowski, M., Ramgopal, R., & Williams, D. (Eds.), Washington Manual of Medical Therapeutics (35th ed.). Wolters Kluwer Health. https://www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602655/all/Tricyclic_Antidepressants
Tricyclic Antidepressants [Internet]. In: Bhat PP, Dretler AA, Gdowski MM, Ramgopal RR, Williams DD, editors. Washington Manual of Medical Therapeutics. Wolters Kluwer Health; 2016. [cited 2023 March 24]. Available from: https://www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602655/all/Tricyclic_Antidepressants.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Tricyclic Antidepressants
ID - 602655
ED - Williams,Dominique,
ED - Bhat,Pavat,
ED - Dretler,Alexandra,
ED - Gdowski,Mark,
ED - Ramgopal,Rajeev,
BT - Washington Manual of Medical Therapeutics
UR - https://www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602655/all/Tricyclic_Antidepressants
PB - Wolters Kluwer Health
ET - 35
DB - The Washington Manual
DP - Unbound Medicine
ER -